



December 16, 2014

## **Kite Pharma Added to the NASDAQ Biotechnology Index**

SANTA MONICA, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced today that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI), which will become effective upon market open on Monday, December 22, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index please visit <https://indexes.nasdaqomx.com/Index/Overview/NBI>.

### **About Kite Pharma**

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit [www.kitepharma.com](http://www.kitepharma.com).

CONTACT: Kite Contacts:

Cynthia M. Butitta

Chief Financial Officer and Chief Operating Officer

310-824-9999

For Media: Justin Jackson

For Investor Inquiries: Nancy Yu

Burns McClellan

(212) 213-0006

[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

[nyu@burnsmc.com](mailto:nyu@burnsmc.com)